Sequana Medical NV
XBRU:SEQUA
Sequana Medical NV
Capital Expenditures
Sequana Medical NV
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sequana Medical NV
XBRU:SEQUA
|
Capital Expenditures
-€66.2k
|
CAGR 3-Years
55%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Nyxoah SA
XBRU:NYXH
|
Capital Expenditures
-€1.2m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-87%
|
CAGR 10-Years
N/A
|
|
|
Ion Beam Applications SA
XBRU:IBAB
|
Capital Expenditures
-€8.2m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
Sequana Medical NV
Glance View
Sequana Medical NV is a commercial stage medical device company, which engages in the design, development, manufacture, and commercialization of medical device. The company is headquartered in Ghent, Oost-Vlaanderen and currently employs 60 full-time employees. The company went IPO on 2019-02-11. The firm focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.
See Also
What is Sequana Medical NV's Capital Expenditures?
Capital Expenditures
-66.2k
EUR
Based on the financial report for Jun 30, 2025, Sequana Medical NV's Capital Expenditures amounts to -66.2k EUR.
What is Sequana Medical NV's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
21%
Over the last year, the Capital Expenditures growth was 90%. The average annual Capital Expenditures growth rates for Sequana Medical NV have been 55% over the past three years , 21% over the past five years .
